Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
Scientists develop new method to deliver cancer-fighting drugs directly to milk ducts

Scientists develop new method to deliver cancer-fighting drugs directly to milk ducts

One of every eight women in the United States will develop breast cancer. Though the incidence of breast cancer began decreasing in 2000, it is still the second-leading cause of cancer death in women. [More]
Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013. [More]
Chemical engineers design way to manufacture peptides in mere hours

Chemical engineers design way to manufacture peptides in mere hours

Small protein fragments, also called peptides, are promising as drugs because they can be designed for very specific functions inside living cells. Insulin and the HIV drug Fuzeon are some of the earliest successful examples, and peptide drugs are expected to become a $25 billion market by 2018. [More]

Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015. [More]
Adherent stromal cells derived from human placenta improve tendon healing, shows study

Adherent stromal cells derived from human placenta improve tendon healing, shows study

According to Dr. Scott Rodeo of New York's Hospital for Special Surgery (HSS), although the findings of a recent study should be considered preliminary, adherent stromal cells derived from human placenta appear promising as a readily available cell source to aid tendon healing and regeneration. [More]
Researchers find effective strategy to eliminate cancer stem-like cells

Researchers find effective strategy to eliminate cancer stem-like cells

Combining nanodrug-based chemotherapy and cryoablation provides an effective strategy to eliminate cancer stem-like cells (CSCs) the root of cancer resistance and metastasis, which will help to improve the safety and efficacy of treating malignancies that are refractory to conventional therapies. [More]
Eveon and Leti fabricate smart micro-pump for drug delivery

Eveon and Leti fabricate smart micro-pump for drug delivery

Eveon and CEA-Leti today announced the demonstration of liquid-pumping for smart drug delivery in the bolus mode using a silicon-based micro-pump fabricated with a standard MEMS process. [More]

Surefire Medical's new line of Surefire Guiding Catheters receive FDA clearance and CE Mark

Surefire Medical, Inc., developer of a new class of infusion systems designed to maximize direct-to-tumor drug delivery, announced today that the company has received 510(k) FDA clearance and the CE Mark for its enhanced line of Surefire Guiding Catheters used in radioembolization and chemoembolization procedures. [More]

Discovery Laboratories reports net loss of $11.7 million for fourth quarter 2013

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the fourth quarter ended December 31, 2013, as well as recent business updates. [More]
Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013. [More]
Orexo signs multi-year agreement with OptumRx and UnitedHealth Group

Orexo signs multi-year agreement with OptumRx and UnitedHealth Group

Orexo AB, the manufacturer of ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII), announced a multi-year agreement with UnitedHealth Group® and OptumRx® providing preferred coverage and reimbursement of ZUBSOLV®. [More]

Research report on the international prefilled syringes market

Research and Markets have announced the addition of the "Concise Analysis of the International Prefilled Syringes Market - Forecasts to 2019" report to their offering. [More]

CT scans predict effectiveness of chemotherapy for pancreatic cancer

Computed tomography (CT) scans routinely taken to guide the treatment of pancreatic cancer may provide an important secondary benefit. According to new research from The University of Texas MD Anderson Cancer Center, the scans also reflect how well chemotherapy will penetrate the tumor, predicting the effectiveness of treatment. [More]

Columbia Laboratories repurchases Actavis' block of shares at advantageous price

Columbia Laboratories, Inc. announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. [More]
New hydrogel actuator has potential to interact safely with living tissues

New hydrogel actuator has potential to interact safely with living tissues

Protein from a small, tasty mollusk inspired Michigan Technological University's Bruce P. Lee to invent a new type of hydrogel actuator. [More]

Neos Therapeutics completes private financing round, raises $15.5M

Neos Therapeutics, Inc. ("Neos" or "the Company"), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has completed an oversubscribed round of private financing, raising a total of $15.5 million. [More]

Frost & Sullivan: Smart pills industry estimated to reach new peak in next five to seven years

The increasing need for convenient diagnostic and accurate therapeutic tools is driving innovation in smart pills. While certain smart pill applications, such as imaging and sensing, have been successfully commercialized, others like drug delivery and surgery are yet to be proven clinically. [More]
Nanomedicine – past, present and future: an interview with Frank Boehm, CEO NanoApps Medical Inc.

Nanomedicine – past, present and future: an interview with Frank Boehm, CEO NanoApps Medical Inc.

The fundamental discipline of nanotechnology is poised to change virtually every aspect of our lives, in just about any sector we can think of. [More]
Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA. [More]
Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection. [More]